A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity

Oncogene

Volumn 26, Issue 8, 2007, Pages 1178-1187

  Yu, W ^a,b   Imoto, I ^a,c   Inoue, J ^a,c   Onda, M ^d   Emi, M ^d   Inazawa, J ^a,b,c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Ctr of Excellence Prog for Frontier Res on Molec Destruction and Reconstr of Tooth and Bone   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Amplification; Array CGH; ATC; DUSP26; p38

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DUSP26 GENE; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; THYROID CANCER;

APOPTOSIS; CARCINOMA; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CLONING, MOLECULAR; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-TYROSINE-PHOSPHATASE; RNA, SMALL INTERFERING; THYROID NEOPLASMS;

EID: 33847219580     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209899     Document Type: Article

References (45)

1. Bishop JM. (1991). Molecular themes in oncogenesis. Cell 64: 235-248.
2. Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O et al. (2001). Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 411: 102-107.
3. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA et al. (2002). Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31: 210-215.
4. Bulavin DV, Fornace AJ. (2004a). P38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92: 95-118.
5. Arf pathway. Nat Genet 36: 343-350.
6. ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2: 148-155.
7. Campisi J. (1996). Relative senescence: an old lives' tale? Cell 84: 497-500.
8. SAPK2-dependent manner. J Biol Chem 275: 35091-35097.
9. Chang L, Karin M. (2001). Mammalian MAP kinase signaling cascades. Nature 410: 37-40.
10. Dixon D, Moyana T, King MJ. (1998). Elevated expression of the cdc25A protein phosphatase in colon cancer. Exp Cell Res 240: 236-243.
11. Garcia MJ, Pole J, Chin SF, Teschendorff A, Naderi A, Ozdag H et al. (2005). A 1-Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 24: 5235-5245.
12. Hoornaert I, Marynen P, Goris J, Sciot R, Baens M. (2003). MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced transformation. Oncogene 22: 7728-7736.
13. Hu Y, Mivechi NF. (2006). Association and regulation of heat shock transcription factor 4b with both extracellular signal-regulated kinase mitogen-activated protein kinase and dual-specificity tyrosine phosphatase DUSP26. Mol Cell Biol 26: 3282-3294.
14. Inazawa J, Inoue J, Imoto I. (2004). Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 95: 559-563.
15. Imoto I, Yuki Y, Sonoda I, Ito T, Shimada Y, Imamura M et al. (2003). Identification of ZASC1, encoding a Kruppel-like zinc finger protein, as a novel target for 3q26 amplification in esophageal squamous cell carcinomas. Cancer Res 63: 5691-5696.
16. Izumi H, Inoue J, Yokoi S, Hosoda H, Shibata T, Sunamori M et al. (2005). Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet 14: 997-1007.
17. Juretic N, Santibanez JF, Hurtado C, Martinez J. (2001). ERK 1,2 and p38 pathways are involved in the proliferative stimuli mediated by urokinase in osteoblastic SaOS-2 cell line. J Cell Biochem 83: 92-98.
18. Liu B, Fang M, Lu Y, Lu Y, Mills GB, Fan Z. (2001). Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer 85: 303-311.
19. McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM. (2005). Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 280: 20995-21003.
20. INK4a expression during cellular senescence. Nature 409: 1067-1070.
21. Onda M, Emi M, Yoshida A, Miyamoto S, Akaishi J, Asaka et al. (2004). Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25344 Genes. Endocr Relat Cancer 11: 843-854.
22. Ono K, Han J. (2000). The p38 signal transduction pathway activation and function. Cell Signalling 12: 1-13.
23. Park JM, Greten FR, Li ZW, Karin M. (2002). Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 297: 2048-2051.
24. Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H et al. (1999). Anaplastic (undifferentiated) thyroid carcinoma (ATC): a retrospective analysis. Langenbecks Arch Surg 384: 284-293.
25. Ray ME, Yang ZQ, Albertson D, Kleer CG, Washburn JG, Macoska JA et al. (2004). Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res 64: 40-47.
26. Sherman SI. (2003). Thyroid carcinoma. Lancet 361: 501-511.
27. Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U et al. (2001). High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 61: 4514-4519.
28. Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC et al. (2005). Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 24: 4232-4242.
29. Srikanth S, Franklin CC, Duke RC, Kraft AS. (1999). Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem 199: 169-178.
30. Takada H, Imoto I, Tsuda H, Nakanishi Y, Ichikura T, Mochizuki H et al. (2005). ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 24: 8051-8060.
31. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H et al. (2000). p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19: 6517-6526.
32. Tanoue T, Yamamoto T, Maeda R, Nishida E. (2001). A novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs. J Biol Chem 276: 26629-26639.
33. Theillet C, Adelaide J, Louason G, Bonnet-Dorion F, Jacquemier J, Adnane J et al. (1993). FGFR1 and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer 7: 219-226.
34. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y et al. (2005). High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA 102: 9625-9630.
35. Vasudevan SA, Skoko J, Wang K, Burlingame SM, Patel PN, Lazo JS et al. (2005). MKP-8, a novel MAPK phosphatase that inhibits p38 kinase. Biochem Biophys Res Commun 330: 511-518.
36. Wada T, Penninger JM. (2004). Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23: 2838-2849.
37. Walentinsson A, Helou K, Wallenius V, Hedrich HJ, Szpirer C, Levan G. (2001). Independent amplification of two gene clusters on chromosome 4 in rat endometrial cancer: identification and molecular characterization. Cancer Res 22: 8263-8273.
38. Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, Huang S et al. (2002). Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 22: 3389-3403.
39. Weinberg RA. (1995). The molecular basis of oncogenes and tumor suppressor genes. Ann NY Acad Sci 758: 331-338.
40. Widmann C, Gibson S, Jarpe MB, Johnson GL. (1999). Mitogen-activated protein kinase: conservation of a three kinase module from yeast to human. Physiol Rev 79: 143-180.
41. Wiseman SM, Loree TR, Rigual NR, Hicks WL, Douglas WG, Anderson GR et al. (2003). Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 25: 662-670.
42. Wu JJ, Bennett AM. (2005). Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. J Biol Chem 280: 16461-16466.
43. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. (2004). Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 64: 1757-1764.
44. Yosimichi G, Nakanishi T, Nishida T, Hattori T, Takano-Yamamoto T, Takigawa M. (2001). CTGF/Hcs24 induces chondrocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extracellular-signal regulated kinase (ERK). Eur J Biochem 268: 6058-6065.
45. Yu W, Inoue J, Imoto I, Matsuo Y, Karpas A, Inazawa J. (2003). GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines. J Hum Genet 48: 331-335.